Abstract
The human monovalent rotavirus vaccine RIX4414 (Rotarix®) is indicated for the prevention of rotavirus gastroenteritis (RVGE) in infants aged 6 to 24 weeks in the EU. It offers broad sustained protective efficacy against RVGE including severe cases, and reduces the incidence of associated hospitalizations. It does not interfere with the immunogenicity of other paediatric vaccinations, and is considered safe.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
